

# Using breast density with the Tyrer-Cuzick risk model

# Use a validated breast density assessment<sup>1</sup>

Average Volpara Volumetric Breast Density percentage (VBD%)

ACR BI-RADS<sup>®</sup> Atlas 4th Edition mapped to 5th Edition values:

 $1 \rightarrow a$   $2 \rightarrow b$   $3 \rightarrow c$   $4 \rightarrow d$ 

## 2 Understand the differences between the validated breast densities

Volpara Volumetric Breast Density %	BI-RADS 4th Edition mapped to a, b, c, d
Objective, continuous measurement of breast density	Subjective, stepwise grade of breast density
Excellent agreement to MRI <sup>3</sup>	Agreement dependent on radiologist experience <sup>4</sup>

## Lifetime Risk Using Volpara<sup>®</sup> Scorecard<sup>™</sup> average VBD% is continuous:



Volumetric breast density gives a true reflection of risk because of the continuous nature of both the risk and density calculation. Configure competing mortality

If using % Lifetime Risk, make sure competing mortality\* is turned **on**. If this is not turned on, it may erroneously inflate risk—especially in young women.<sup>5</sup> \*Calculation includes possibility of death from non-cancer causes.

## Use the model correctly

 $(\mathbf{3})$ 

5

Fill in as much information as possible, but don't guess. It's **ok** if a woman doesn't know an answer. The model will simply use the population average for her age.

## Use only high-quality images

The risk of developing breast cancer is unknown for women who have implants or have had breast surgery. Density is also hard to judge automatically or visually on blurred or poorly positioned images.



## What is the Tyrer-Cuzick breast cancer risk model?

The Tyrer-Cuzick model, or IBIS tool, is used to identify women who may be at a higher risk of developing breast cancer over time. It does not predict masking risk. When used correctly, it identifies women who may benefit from supplemental screening such as MRI, ultrasound, and genetic testing.<sup>2</sup>



## Using breast density with the Tyrer-Cuzick model

Real-life example



**Risk Factors** Age: 47 Height: 1.62 m Weight: 59 kg Premenopausal Nulliparous Grandmother: breast cancer at age 68

#### Input average Breast Density % for validated risk



Using the highest VBD is not validated and would result in the **lifetime risk increasing from 20.7% to 21.6%**.

#### Turn on competing mortality for validated risk



Turning competing mortality off would erroneously inflate this woman's **lifetime risk** from 20.7% to 24.8%.

## Include as many family members as possible



Personal information Age: 47 Height: 1.62 m Weight: 59 kg Premenopausal Nulliparous Average VBD 15.6%



Family history with cancer Maternal grandmother: breast cancer at age 68 Lifetime risk = 20.7%



Complete family information Maternal grandmother: breast cancer age 68 3 maternal aunts (no cancer) 2 paternal aunts (no cancer) 4 sisters (no cancer) Lifetime risk = 17.2%

#### Contact

info@volparahealth.com support@volparahealth.com AUS +61 1800 370 623 NZ +64 0800 444 148 Europe +44 203 051 1029 USA +1 800 305 3865

### Connect

f @VolparaHealth

💟 @volpara

vs

in Volpara Health

Eom, H.-J. et al. Comparison of variability in breast density assessment by BI-RADS category according to the level of experience. Acta Radiologica 59, 527–532 (2018).
Himes, D.O., Root, A.E., Gammon, A. & Luthy, K.E. Breast Cancer Risk Assessment: Calculating Lifetime Risk Using the Tyrer-Cuzick Model. The Journal for Nurse Practitioners 12, 581–592 (2016).

References

 Brentnall, A.R. et al. A Case-Control Study to Add Volumetric or Clinical Mammographic Density into the Tyrer-Cuzick Breast Cancer Risk Model. Journal of Breast Imaging (2019).
Terry, M.B. et al. 10-year performance of four models of breast cancer risk: a validation study. Lancet Oncol 20, 504–517 (2019).

3. Sartor, H. et al. Measuring mammographic density: comparing a fully automated volumetric assessment versus European radiologists' qualitative classification. Eur Radiol 26, 4354–4360 (2016).